ArticleOncology letters2020
Cardamonin as a potential treatment for melanoma induces human melanoma cell apoptosis.
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Cardamonin as a potential anticancer agent: Preclinical insights and clinical implications.World journal of clinical oncology · 2025Review
- Magnesium phosphate functionalized graphene oxide and PLGA composite matrices with enhanced mechanical and osteogenic properties for bone regeneration.Regenerative biomaterials · 2025Article
- Deciphering the Potentials of Cardamom in Cancer Prevention and Therapy: From Kitchen to Clinic.Biomolecules · 2024Review
- Anticancer Potential of Natural Chalcones: In Vitro and In Vivo Evidence.International journal of molecular sciences · 2023Review
- Eupalinolide O Induces Apoptosis in Human Triple-Negative Breast Cancer Cells via Modulating ROS Generation and Akt/p38 MAPK Signaling Pathway.Journal of oncology · 2022Article
- Ethnomedicinal uses of Indian spices used for cancer treatment: A treatise on structure-activity relationship and signaling pathways.Current research in food science · 2022Review
- Preparation of Chlorophyll Nanoemulsion from Pomelo Leaves and Its Inhibition Effect on Melanoma Cells A375.Plants (Basel, Switzerland) · 2021Article
- Review
- Cardamonin Attenuates Experimental Colitis and Associated Colorectal Cancer.Biomolecules · 2021Article
- Anti-Cancer Effects ofMolecules (Basel, Switzerland) · 2020Article
- An overview of the potential anticancer properties of cardamonin.Exploration of targeted anti-tumor therapy · 2020Review
- Cardamonin Promotes the Apoptosis and Chemotherapy Sensitivity to Gemcitabine of Pancreatic Cancer Through Modulating the FOXO3a-FOXM1 Axis.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
2',4'-dihydroxy-6'-methoxychalcone (cardamonin) is a natural compound with anti-proliferative effects on several cancer types including nasopharyngeal carcinoma. The effects of cardamonin on melanoma cells are unknown. The present study investigated the anti-proliferative effect of cardamonin on human melanoma cell lines (M14 and A375), and the underlying apoptosis inducing mechanisms. MTS assay showed that cardamonin inhibited M14 cells viability, and a reduction of the M14 cell density was also observed. Flow cytometry showed that cardamonin induced M14 cells apoptosis in a dose-dependent manner. Western blot analysis showed protein expression in M14 and A375; the pro-apoptotic protein BAX was upregulated, while the anti-apoptotic protein B-cell lymphoma-2 was downregulated. The protein expression of cleaved caspase-8, -9 and cleaved poly (ADP-ribose) polymerase was increased, whereas P65 was decreased. Furthermore, cardamonin inhibited M14 cell migration. These findings suggest that cardamonin may be a novel anticancer treatment for human melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.